Subcutaneous Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen
Status:
Completed
Trial end date:
2019-03-22
Target enrollment:
Participant gender:
Summary
The aim of this clinical phase I single centre, randomized, double-blind, placebo-controlled
study with open comparator is to investigate tolerability and safety as well as the
immunological effects of BM41 in comparison to placebo (double blind) and to a standard
subcutaneous immunotherapy Alutard SQ (open) in birch allergic patients.
Phase:
Phase 1
Details
Lead Sponsor:
Odense University Hospital
Collaborators:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Biomay AG European Commission University of Salzburg